Follow BellaSeno for the latest company news, industry events, and regenerative medicine updates. Explore our latest media and announcements below.
Sign Up to Our Newsletter →
Following positive two-year human clinical data from its scaffold-guided regenerative program, BellaSeno has announced an exclusive global licensing agreement with Mentor Worldwide LLC, a Johnson & Johnson company.
This collaboration will bring together BellaSeno’s technology alongside the clinical, regulatory and commercial scale of one of the world’s leading healthcare companies. As breast aesthetics continues to evolve, there is growing demand for approaches that expand the range of solutions available to patients and surgeons. This collaboration will help accelerate the final clinical development of the breast scaffold platform as BellaSeno prepares for global market introduction.
BellaSeno Demonstrates Superior Biomechanical Properties of its 3-D Printed, Resorbable Scaffolds for Bone Reconstruction
June 20, 2023
.jpg)
Positive Interim Data of BellaSeno’s Clinical Trial with Resorbable Breast and Chest Implants Reported at RACS 2023
May 9, 2023
BellaSeno Starts Two Clinical Trials of its Resorbable Breast and Chest Implants
August 3, 2022
Pectus excavatum camouflage
November 11, 2021
The first-in-human trial of soft tissue engineering to camouflage a pectus excavatum defect not reconstructable by conventional techniques.
BellaSeno’s regenerative scaffold platform has been featured across international media, clinical discussions, and industry publications as interest grows in the future of soft-tissue restoration and scaffold-guided regeneration.
Deutscher Platz 5A
04103 Leipzig
Germany
4 Starling Street
Burliegh Heads
QLD, Australia, 4220
